ArticleMaterials today. Bio2025
Targeting drug cocktail hydrogel platform for inhibiting tumor growth and metastasis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Recent advances in application of hydrogel-based nanomaterials in breast cancer: from drug delivery, immunotherapy mechanisms to clinical applications.Journal of nanobiotechnology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination therapy could overcome the limitation of monotherapy to inhibit tumor recurrence and metastasis, but is usually constrained by complex fabrication processes. Here, a tunable hydrogel platform was developed using different silk nanocarriers, which independently achieve flexible functional optimization of various drugs. Silk nanorods (SNR) were modified with cRGDfK peptides to achieve targeting ability to tumor vessels and then loaded with hydrophobic vascular inhibitor Combretastatin A4 (CA4). The loading of CA4 and the targeted modification could be tuned to enhance the destruction of tumor vessels. Both hydrophilic doxorubicin (DOX) and hydrophobic paclitaxel (PTX) were co-loaded on silk nanofibers (SNF) to form injectable hydrogels with optimized combination chemotherapy. The drug-laden SNR and SNF were blended directly to form injectable hydrogels without the compromise of drug biological activity. Both the targeting modification of SNR and the optimized co-delivery of DOX and PTX improved the therapeutic efficiency
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.